BioPharmSignal logoBioPharmSignal

Biotech News

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma (LYEL)Lyell ImmunopharmaConference / presentation

SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior

Open original release

Related news

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

COGTCogent Biosciences2026-05-27 12:00 EST

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

IDYAIDEAYA Biosciences2026-05-26 10:00 EST

IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

LYELLyell Immunopharma2026-05-12 12:00 EST

Lyell Immunopharma Announces Participation in May Investor Conferences

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

ERASErasca2026-05-27 12:00 EST

Erasca to Present at the Jefferies Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

KURAKura Oncology2026-05-06 11:30 EST

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

View all latest news

Lyell Immunopharma

Lyell Immunopharma is a cell-therapy company focused on reprogramming T cells for durable cancer treatment. Its work centers on improving persistence and potency in cellular immunotherapy.

Recent company news

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

LYELLyell Immunopharma2026-05-12 12:00 EST

Lyell Immunopharma Announces Participation in May Investor Conferences

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

LYELLyell Immunopharma2026-04-07 12:00 EST

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

LYELLyell Immunopharma2026-03-12 20:05 EST

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Stock data

Close
12.96 USD
Market cap
347.44M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States